title: Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study.
abstract: OBJECTIVE
  The purpose of the study is to investigate the efficacy of an alpha-1 adrenergic receptor antagonist (silodosin) for the treatment of lower urinary tract symptoms (LUTS) associated with interstitial (125)I implantation for prostate cancer.
  
  
  METHODS
  This randomized single-center study involved 105 patients (53 with and 52 without silodosin). Silodosin was postoperatively administered, daily, for 6 months (8 mg/day). Urinary symptoms and pressure flow were evaluated preoperatively and postoperatively at 1, 3, 6, and 12 months.
  
  
  RESULTS
  At 12 months, interstitial (125)I implantation had induced a significant decrease in prostate volume (28.3 ± 11.1-20.5 ± 8.1 g in the silodosin group and 26.1 ± 9.7-17.7 ± 4.9 g in the controls) and the prostate-specific antigen level (7.1 ± 3.6-1.4 ± 1.7 ng/mL in the silodosin group and 8.1 ± 4.3-1.3 ± 1.2 ng/mL in the controls). Significant improvements in the international prostate symptom voiding subscores at 6 months and quality of life at 3 months were observed in those receiving silodosin. The pressure flow studies demonstrated that silodosin had significantly enlarged the bladder capacity when the first non-voiding contraction was seen at 3 and 12 months (3M: 127.1 ± 74.8 vs. 118.2 ± 83.9 mL, p = 0.001; 12M: 123.7 ± 79.3 vs. 100.3 ± 73.4 mL, p = 0.01); however, there were no improvements in the bladder outlet obstruction index (BOOI) or urinary flow.
  
  
  CONCLUSIONS
  Silodosin temporarily improved LUTS, but did not improve the BOOI after (125)I implantation in the prostate.
authors.affiliation: Department of Urology, Faculty of Medicine, Kinki University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan, shimizun@med.kindai.ac.jp.
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Shimizu
authors.forename: Takafumi
authors.initials: T
authors.lastname: Minami
authors.forename: Koichi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Saito
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Taiji
authors.initials: T
authors.lastname: Hayashi
authors.forename: Hidenori
authors.initials: H
authors.lastname: Tsuji
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nozawa
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Tokumi
authors.initials: T
authors.lastname: Ishii
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Uemura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Nakamatsu
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology / Q000532:radiotherapy*; D011788:Quality of Life; D016896:Treatment Outcome; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D007211:Indoles; C095285:silodosin